{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:47:48Z","timestamp":1759178868416},"reference-count":16,"publisher":"American Diabetes Association","issue":"3","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,3,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Irbesartan was renoprotective independently of its blood pressure-lowering effect in the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA2) study. However, blood pressure was evaluated by trough office blood pressure (OBP), which may underestimate reductions in 24-h ambulatory blood pressure (ABP). In the present study, we evaluated 24-h blood pressure patterns in a subpopulation of the IRMA2 trial.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014Type 2 diabetic patients (n = 43) with persistent microalbuminuria (as determined by repeated overnight measurements of urinary albumin excretion [UAE]) and hypertension who were included in the IRMA2 study at the Steno Diabetes Center were subjected to 24-h ABP (Takeda, TM2420) measurements before and 2 years after randomization to placebo (n = 15), irbesartan 150 mg daily (Irb150; n = 13), or irbesartan 300 mg daily (Irb300; n = 15).<\/jats:p>\n               <jats:p>RESULTS\u2014At baseline, the placebo, Irb150, and Irb300 groups were comparable: OBP: 157 \u00b1 15\/89 \u00b1 7, 156 \u00b115\/91 \u00b1 11, and 159 \u00b1 16\/90 \u00b1 9 mmHg (NS); 24-h ABP: 148 \u00b1 13\/83 \u00b1 11, 148 \u00b1 16\/82 \u00b1 7 and 147 \u00b1 16\/81 \u00b1 10 mmHg (NS); and UAE (geometric mean with 95% CI): 43 (32\u201357), 46 (30\u201370), and 59 (42\u201385) \u03bcg\/min (NS), respectively. We found that 2 years after randomization, OBP was significantly reduced in all three groups (by 11\/7, 13\/8, and 13\/8 mmHg in the placebo, Irb150, and Irb300 groups, respectively), but that there were no significant differences among groups. Reductions in 24-h ABP were similar in the three groups (11\/10, 5\/7, and 7\/8 mmHg, respectively; NS), as were reductions in day ABP (11\/9, 7\/7, and 8\/9 mmHg, respectively; NS) and night ABP (4\/11, 7\/7, and 3\/3 mmHg, respectively; NS). The reduction in UAE at the end of the study was 0% (\u221286 to 42), 38% (\u221214 to 66), and 73% (59 to 82), respectively (overall, P &amp;lt; 0.01).<\/jats:p>\n               <jats:p>CONCLUSION\u2014Irbesartan is renoprotective independently of its beneficial effect in lowering 24-h blood pressure in patients with type 2 diabetes and persistent microalbuminuria.<\/jats:p>","DOI":"10.2337\/diacare.26.3.569","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"569-574","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":21,"title":["Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure"],"prefix":"10.2337","volume":"26","author":[{"given":"Kasper","family":"Rossing","sequence":"first","affiliation":[{"name":"Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per K.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Andersen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hovind","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Post","family":"Hansen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark"},{"name":"Faculty of Health Science, University of Aarhus, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031220312861300_R1","doi-asserted-by":"crossref","unstructured":"Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet\u2008359: 1004\u20131010, 2002","DOI":"10.1016\/S0140-6736(02)08090-X"},{"key":"2022031220312861300_R2","doi-asserted-by":"crossref","unstructured":"Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med\u2008329: 1456\u20131462, 1993","DOI":"10.1056\/NEJM199311113292004"},{"key":"2022031220312861300_R3","doi-asserted-by":"crossref","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med\u2008345: 870\u2013878, 2001","DOI":"10.1056\/NEJMoa011489"},{"key":"2022031220312861300_R4","doi-asserted-by":"crossref","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med\u2008345: 861\u2013869, 2001","DOI":"10.1056\/NEJMoa011161"},{"key":"2022031220312861300_R5","doi-asserted-by":"crossref","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med\u2008345: 851\u2013860, 2001","DOI":"10.1056\/NEJMoa011303"},{"key":"2022031220312861300_R6","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet\u2008355: 253\u2013259, 2000","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"2022031220312861300_R7","doi-asserted-by":"crossref","unstructured":"Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension\u200838: E28\u2013E32, 2001","DOI":"10.1161\/hy1101.099502"},{"key":"2022031220312861300_R8","unstructured":"Parving H-H, \u00d8sterby R, Ritz E: Diabetic nephropathy. In The Kidney. Brenner BM, Levine S, Eds. Philadelphia, WB Saunders, 2000, p. 1731\u20131773"},{"key":"2022031220312861300_R9","doi-asserted-by":"crossref","unstructured":"Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation\u2008103: 1869\u20131874, 2001","DOI":"10.1161\/01.CIR.103.14.1869"},{"key":"2022031220312861300_R10","doi-asserted-by":"crossref","unstructured":"Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol\u200819: 1992\u20131997, 1999","DOI":"10.1161\/01.ATV.19.8.1992"},{"key":"2022031220312861300_R11","doi-asserted-by":"crossref","unstructured":"Casiglia E, Zanette G, Mazza A, Donadon V, Donada C, Pizziol A, Tikhonoff V, Palatini P, Pessina AC: Cardiovascular mortality in non-insulin-dependent diabetes mellitus: a controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. Eur J Epidemiol\u200816: 677\u2013684, 2000","DOI":"10.1023\/A:1007673123716"},{"key":"2022031220312861300_R12","doi-asserted-by":"crossref","unstructured":"Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med\u20087: 35\u201343, 2002","DOI":"10.1191\/1358863x02vm412ra"},{"key":"2022031220312861300_R13","doi-asserted-by":"crossref","unstructured":"White WB, Pickering TG, Morganroth J, James GD, McCabe EJ, Moucha O, Hunter H: A multicenter evaluation of the A&D TM-2420 ambulatory blood pressure recorder. Am J Hypertens\u20084: 890\u2013896, 1991","DOI":"10.1093\/ajh\/4.11.890"},{"key":"2022031220312861300_R14","doi-asserted-by":"crossref","unstructured":"Nielsen FS, Rossing P, Bang LE, Svendsen TL, Gall M-A, Smidt UM, Parving H-H: On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes\u200844: 783\u2013789, 1995","DOI":"10.2337\/diabetes.44.7.783"},{"key":"2022031220312861300_R15","doi-asserted-by":"crossref","unstructured":"Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G: The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens\u200816: 1685\u20131691, 1998","DOI":"10.1097\/00004872-199816110-00016"},{"key":"2022031220312861300_R16","doi-asserted-by":"crossref","unstructured":"Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH: White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care\u200820: 859\u2013863, 1997","DOI":"10.2337\/diacare.20.5.859"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/3\/569\/665322\/dc0303000569.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/3\/569\/665322\/dc0303000569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T22:32:25Z","timestamp":1647124345000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/26\/3\/569\/29188\/Comparative-Effects-of-Irbesartan-on-Ambulatory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.26.3.569","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3,1]]}}}